• We developed a prediction model for postthrombotic syndrome (PTS) after deep vein thrombosis (DVT).
Summary. Background: Postthrombotic syndrome (PTS) is a chronic complication that develops in 20-50% of patients after deep vein thrombosis (DVT). Although individual risk factors for PTS have been characterized, the ability to predict which DVT patients are likely to develop PTS remains limited. Objective: To develop a clinical prediction score for PTS in patients with DVT. Methods: The derivation cohort consisted of participants in the SOX Trial, a randomized double-blind placebo-controlled trial of elastic compression stockings versus placebo stockings worn for 2 years after DVT to prevent PTS in patients with a first proximal DVT, enrolled in 24 community and tertiary-care hospitals from 2004 to 2010. Multivariable logistic regression analysis of baseline characteristics was performed. The outcome was the occurrence of PTS, diagnosed starting from 6 months or later according to Ginsberg's criteria. Results: Seven hundred and sixty-two patients were included in the analysis. The median follow-up was 728 days. The model includes three independent predictors, and has a range of possible scores from 0 to 5. High-risk predictors were: index DVT in the iliac vein; body mass index of ≥ 35 kg m À2 ;
Introduction
Postthrombotic syndrome (PTS) is a chronic complication of deep vein thrombosis (DVT) that occurs in 20-50% of patients after DVT, depending, in part, on the scale used to diagnose PTS [1] [2] [3] . Its clinical features range from minor limb swelling and discomfort to severe leg pain, intractable edema, irreversible skin changes, and leg ulceration [1] [2] [3] . PTS reduces quality of life [4] and imposes a substantial economic burden on patients and society [5, 6] . Clinical predictors of PTS have been progressively characterized. Established independent clinical predictors at DVT diagnosis include extensive (iliac or common femoral) DVT [1, [7] [8] [9] , high body mass index (BMI) [1, 2, [9] [10] [11] [12] [13] [14] , and recurrent ipsilateral DVT [13, 15, 16] . Age [1, 9, 11, 12, 14, [16] [17] [18] and sex [1, 9, 12, 18, 19] have been variably associated with PTS risk. In a previous study by our group, the severity of venous symptoms and signs as measured according to the Villalta scale 1 month after DVT diagnosis was also independently predictive of PTS development [1] .
Despite the progress in our knowledge regarding risk factors for PTS, the ability to combine information to predict, on an individual basis, which patients with DVT are likely to develop PTS remains limited. Identifying patients at high risk of developing PTS would allow physicians to provide patients with individualized information on their expected prognosis, and is important for selection of the best candidates for preventive strategies for PTS. Therefore, we aimed to develop a multivariable prognostic prediction model for PTS development in patients with a first proximal DVT, using clinical variables available at the time of DVT diagnosis.
Methods

Sampling design
We used the SOX Trial cohort [20] for derivation of a clinical prediction rule. The SOX Trial was a multicenter (24 Canadian and US community hospitals and tertiary-care hospitals; see the Appendix for a complete list of investigators), randomized, double-blind, placebo-controlled trial of patients with a first episode of acute proximal DVT enrolled between June 2004 and February 2010. Its primary objective was to evaluate whether elastic compression stockings (ECSs), as compared with placebo stockings, in addition to standard anticoagulation, decreased the incidence of PTS during 2 years of follow-up. Inpatients and outpatients presenting with a first episode of symptomatic proximal DVT (with or without concurrent distal DVT or pulmonary embolism) were potentially eligible to participate. Proximal DVT, which was defined as DVT in the popliteal or more proximal deep leg veins, had to have been objectively confirmed with ultrasound within the previous 14 days. Patients were excluded if they had a contraindication to or inability to apply ECSs, an expected lifespan of < 6 months, geographic inaccessibility to follow-up, or received thrombolytic therapy for the initial treatment of DVT. Patients attended study visits at baseline and 1, 6, 12, 18 and 24 months. The study was approved by the research ethics boards at all participating centers, and written informed consent was obtained from all patients.
Primary outcome measure
The primary outcome measure for both the SOX Trial and the present study was the cumulative incidence of PTS during study follow-up, assessed by trained study personnel starting at the 6-month visit, using Ginsberg's criteria of ipsilateral pain and swelling of at least 1 month in duration that were typical in character (worse at the end of the day or with prolonged sitting or standing, and better after a night's rest and leg elevation) [21] . Local study investigators were required to confirm each case of PTS.
Predictor variables
At study entry, trained research nurses recorded demographic and clinical characteristics by using a standardized case report form, including variables considered to be plausible predictors of PTS based on a priori hypotheses or previously published reports [1, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . These baseline variables included sex, age (categorized into three groups: < 40, 40-64 and ≥ 65 years), ethnicity (defined as Caucasian versus other), highest extent of DVT (defined as iliac versus non-iliac DVT), the presence and severity of DVT signs and symptoms, type of DVT (unprovoked versus secondary risk factors versus malignancy-associated), side of DVT (left versus right), smoking (any versus none), family history of venous thromboembolism (VTE), and BMI (categorized into three groups: < 25, 25-34 and ≥ 35 kg m À2 ). Additionally, because the cohort used to develop the prediction model was composed of a randomized controlled trial (RCT) study population, the predictive effect of the randomly assigned study treatment (i.e. active versus placebo ECSs) was tested in the model (included a priori in the multivariable analysis).
To quantify the severity of DVT symptoms and signs at DVT diagnosis, we used the Villalta scale, which is a reproducible clinical measure (interobserver agreement, j = 0.66, 95% confidence interval [CI] 0.47-0.85) [22] that grades the severity, from 0 (absent) to 3 (severe), of each of five patient-rated symptoms (pain, cramps, heaviness, pruritus, and paresthesia) and six clinician-rated signs (edema, redness, skin induration, hyperpigmentation, venous ectasia, and pain on calf compression) [23] . The presence of leg ulcers was also documented. A higher total Villalta score indicates greater severity of symptoms and signs (0-4, none or minimal; 5-9, mild; 10-14, moderate; and > 14 or leg ulcer, severe), similar to the assignment of severity category when this scale is used to diagnose and classify the severity of PTS at later time points after DVT. Physical signs were assessed by trained study nurses or physicians with the aid of a full-color visual guide to help standardize the assessments [24] .
Secondary DVT was defined as that occurring during pregnancy or postpartum or DVT occurring in a patient with a history of immobilization within the last month or trauma or surgery within the last 3 months. Cancer-related DVT was defined as that occurring in the setting of active malignancy (diagnosed within the last 6 months or metastatic or ongoing treatment or palliative treatment).
Study sample
The complete dataset from the SOX Trial cohort was used for derivation of the prognostic model. Patients who died before the 6-month follow-up visit and patients who were lost to follow-up after the baseline visit were excluded from the analysis. We used actual follow-up time to calculate the median follow-up.
Missing data
We had a complete dataset for all predictor variables. We performed multiple imputation for 44 patients with missing outcome data. Missing values were predicted on the basis of all predictors assessed in the multivariable analysis as stated above. We created 20 copies of the dataset, with the missing values replaced by imputed values drawn from their predicted distribution by use of the observed data. Fully conditional statement was chosen as the imputation method. In this method, regression is used for all continuous variables, and the discriminant function method is used for all classification variables. No interaction terms were included in the imputation model [25] .
Derivation of model
All baseline predictor variables were included in a multivariable logistic regression model, with backward variable elimination. The logistic regression model is most appropriate for our binary endpoint (the occurrence of PTS). We chose a logistic regression model in place of a timeto-event approach for predicting long-term (up to 2 years) prognostic outcome in order to enable multiple imputation for the missing outcome data. A P-value of > 0.05 was used for elimination of variables.
To facilitate the calculation of an individual patient's PTS risk, we developed a score chart. We multiplied the regression coefficients by 2, and rounded them to the nearest integer to assign a score for each of the predictors. The scores for the predictors were added to calculate the final total score, which corresponds to the risk of PTS development during follow-up.
Internal validation
The apparent performance of the selected prediction model was assessed graphically by the use of calibration plots. Calibration plots are based on expected versus observed probabilities. The cohort is sorted by predicted probabilities, and then divided into 10 deciles of equal size and compared with observed probabilities. Calculation of the observed probabilities in each decile was performed by dividing the number of observed occurrences of PTS by the size of the decile. Discrimination was expressed as the c-index. We assessed internal validity with a bootstrapping procedure for a realistic estimate of model performance by random sampling with replacement with 500 iterations [26] . Estimates of the standard error and 95% CIs around the parameters' coefficients were compared with the original regression model. All statistical analyses were performed with SAS statistical software, V 9.3.
Results
Among 803 patients enrolled in the SOX Trial, 762 were included in the derivation cohort. Figure 1 presents patient flow for inclusion in the derivation cohort. Eight hundred and three SOX Trial patients (409 in the active treatment arm, and 394 in the placebo arm) were considered for inclusion in the SOX-PTS score derivation cohort. Of these, 41 patients were excluded, eight because of loss to follow-up after the baseline visit, and 33 patients died before the 6 months visit, therefore outcome data were not available and multiple imputation could not be performed. Data were not available and multiple imputation could not be performed. For all included patients (n = 762), we had a complete set of baseline variables with no missing data. For 44 patients with missing outcome data because of loss to follow-up before the 6-month visit, multiple imputation was performed. The median follow-up was 728 days (interquartile range [IQR] 435-744 days).
After multiple imputation, 90 patients were diagnosed with PTS during study follow-up according to Ginsberg's criteria. All patients received standard anticoagulant therapy consisting of 5-10 days of heparin (usually subcutaneous low molecular weight heparin) and warfarin for 3-6 months or longer to treat their acute DVT [20] . The median duration of anticoagulation for the whole cohort was 185 days (IQR 111-233 days), and did not differ between patients who developed and did not develop PTS (187 days and 185 days, respectively). Table 1 shows the characteristics of the derivation cohort and bivariate analysis according to PTS status at the end of follow-up. As can be seen, 60% of patients were male, 83% were aged > 40 years, and most were Caucasian. The majority (87.5%) were outpatients, and 63% had unprovoked DVT. The bivariate analysis suggested that extent of DVT, baseline Villalta score category, type of DVT, side of DVT and BMI were potentially relevant predictors of PTS. Table S1 compares the baseline characteristics of patients with missing data with those of patients with complete data. There were no statistically significant differences in baseline characteristics between patients with missing outcome data and those with complete data.
The multivariate analysis (Table 2) suggested that only extent of DVT, baseline Villalta score category and BMI were independent predictors of PTS. The model with the best classification performance, which we have termed the SOX-PTS score, includes three independent predictors (Table 3) Table 3 . The scores for the predictors are added to calculate the final total score, which has a range of possible scores from 0 to 5 (Table 4) , and corresponds to the risk of PTS development during follow-up. As only one patient in the derivation cohort had a total score of 5, we considered the highest score to be 4 or higher. High-risk predictors were: (i) index DVT in the iliac vein; (ii) BMI of > 35 kg m
À2
; and (iii) moderate-severe Villalta severity category at DVT diagnosis. As compared with patients with a score of 0, those with a score of ≥ 4 had an odds ratio of 5.9 (95% CI 2.1-16.6) for developing PTS (Table 3) . Table 5 shows model fit statistics and apparent performance. The c-index for the simplified score (i.e. after rounding of the regression coefficients to the nearest integer) was 0.65, whereas the c-index for the score before simplification was 0.66. A calibration plot is shown in Fig. 2 . The b-estimate for the calibration plot was 0.94. Internal validation with the bootstrapping technique is shown in Table 6 . The c-statistic for the bootstrap was 0.65 (95% CI 0.64-0.67). All parameters demonstrated good performance of the model.
Discussion
The SOX Trial cohort provided the opportunity to prospectively assess predictors of PTS in a large number of patients with a first episode of proximal DVT. We were able to identify three independent predictors of PTS (extent of DVT; BMI; and baseline Villalta score category) that could be combined into a model that clearly predicted a low, intermediate and high risk of PTS development. To our knowledge, this is the first described clinical prediction score for PTS. Our results are plausible and consistent with the literature. High BMI is an established risk factor for PTS, and has been found to double the risk of PTS in different cohorts for which different cutoff points were used to define a high BMI [1, 2, [9] [10] [11] [12] [13] [14] . PTS risk is known to be higher in patients with proximal DVT than in those with distal DVT [1, [7] [8] [9] . Proximal DVTs constitute a heterogeneous group, comprising both iliofemoral and femoropopliteal DVT. This distinction is important because, in iliofemoral DVT, the obstruction is often above the entry of the profunda femoral vein, thereby impairing collateral flow and conferring a greater PTS risk than popliteal DVT [12] . Kahn et al. noted a 2.23-point increase in the Villalta score over 2 years of follow-up in patients with iliac or common femoral vein DVT versus those with more distal DVT [1] . Tick et al. reported that DVT in the femoral and iliac veins was associated with an increased PTS risk as compared with popliteal vein thrombosis (relative risk (RR) 1.3; 95% CI 1.1-1.6). [12] . In a study by Labropoulos et al. of patients with a first episode of acute DVT, PTS was more frequent and more severe when the iliac vein was occluded in conjunction with other veins [27] . All of the patients in our study cohort had proximal DVT, and, in agreement with other studies, involvement of the iliac vein was a strong independent predictor of PTS. In the Venous Thrombosis Outcomes (VETO) study, the presence of residual venous symptoms and signs as assessed with the Villalta scale at 1 month after DVT diagnosis was strongly predictive of subsequent PTS. Patients whose residual symptoms at 1 month were mild, moderate or severe had average Villalta scores over 2 years of follow-up that were higher by 2, 5 and 7 points, respectively, than those of patients without residual symptoms at 1 month [1] . As the purpose of the present study was to derive a clinical prediction rule that can be used at the time of DVT diagnosis, we chose to assess the presence and severity of venous signs and symptoms at DVT diagnosis, and found the Villalta score category at baseline to be a strong independent predictor of PTS. This finding is consistent with findings reported by Roberts et al. [28] , who found that the Villalta score at 2 weeks after DVT diagnosis predicted PTS during 6 months of follow-up (n = 70). The mean 2-week Villalta score was significantly higher in those with PTS (8.1 AE 3.7) than in those without PTS (2.6 AE 2.7, P < 0.001), and the adjusted odds ratio for every 1-point increase in the 2-week Villalta score was 1.78 (95% CI 1.19-2.64).
Our findings on the baseline anatomic extent of DVT and severity of DVT symptoms and signs provide additional evidence to support the theory that the volume of thrombosis and/or acute inflammatory reaction may be important underlying mechanistic determinants of PTS development, as our group and others have described previously [29, 30] .
Our study has several strengths. RCTs represent stringently selected prospective cohorts. Information on the predictors and outcomes was systematically obtained, and was therefore less prone to yield biased prediction models. Indeed, we had a complete dataset for baseline variables, only 44 patients were missing an outcome assessment, and there were no significant differences in baseline characteristics between missing and complete case patients. Hence, we can assume that missing patients were missing at random. All available data in the database were used, and multiple imputation was performed for missing outcome data to maximize the power and generalizability of the results. The relatively large size of this derivation cohort is another important strength of this study, increasing its face validity. Methodologically, derivation of this prediction rule was rigorously performed according to the recommended guidelines for clinical prediction rule development [31] . The present study also has potential limitations. As stated above, the derivation cohort is based on data from a randomized trial, and not a prospective cohort designed specifically for this purpose. However, we accounted for this fact by including the treatment arm as a parameter in the multivariable analysis, and it did not influence the final model. Methodological standards for clinical prediction rules state that the blind assessment of predictors for the outcome is recommended. This was not possible, because of the RCT design. However, the baseline clinical findings used as predictive variables were clearly defined and standardized, and their assessment was performed without knowledge of the outcome, which fulfills the TRIPOD criteria [31] . Furthermore, although the assessors were not blinded to baseline predictors, the goal of deriving a clinical prediction rule was formulated only after the trial ended; hence, the assessors were not aware of the attempt to link baseline predictors with subsequent PTS risk. Additional concerns about the generalizability of a model developed by the use of data from a randomized trial might arise because of the (often) extensive exclusion criteria [32] . However, in the SOX Trial, there were very few exclusion criteria, hence our derivation cohort is likely to be representative of general populations of patients with a first proximal DVT, except for ethnicity -as most of the patients in our cohort were Caucasian, this model may not be applicable to non-Caucasian populations. Another point regarding the generalizability of this study pertains to the use of the Ginsberg criteria to define PTS. Ginsbergdefined PTS captures more severe cases of PTS than Villalta-defined PTS. Hence, this study might have captured only the group of patients at highest risk within the broader category of 'any PTS'. This assumption would have to be proven or refuted in future studies. In the SOX-PTS scale, the range of possible scores is 0-5. However, as there was only one patient in our derivation population with a score of 5, we considered the highest score to be 4 or higher. This also accounts for the wide CI around the odds ratio for PTS in this risk category. This highest-risk group (score of 5) might be an important patient population for further investigation, and we suggest that further validation studies using the proposed 0-5 scoring system are needed. Finally, as patients in this cohort were treated with low molecular weight heparin followed by warfarin, the validity of this model in patients treated with direct oral anticoagulants needs to be addressed. In summary, the SOX-PTS score is the first reported clinical prediction rule for PTS. Three baseline patient characteristics, namely, BMI of ≥ 35 kg m À2 , DVT involving the iliac vein, and severe venous symptoms and signs at DVT diagnosis, defined a population of patients at high risk for PTS development. We believe that it is important to be able to identify DVT patients who may have a higher likelihood of developing PTS. Such patients may benefit from closer monitoring after proximal DVT, and from more aggressive strategies to treat acute DVT in the future. The use of this tool could also help to select (i.e. enrich) the patient population for trials of new preventive strategies for PTS, as such higher-risk DVT patients might benefit the most. External validation of the SOX-PTS score is needed before it can be implemented in clinical use.
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